Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates through two main segments: Diagnostic Substances and Therapeutic Development Programs. Central to its efforts is the Manocept platform, which targets the CD206 mannose receptor found on activated macrophages, enabling innovative approaches to diagnostic imaging and therapeutic delivery. This platform supports a variety of diagnostic modalities, including PET imaging, and is designed to address immune and inflammation-related diseases. Notably, Navidea offers NAV4694, a PET imaging agent for assessing Alzheimer’s disease and mild cognitive impairment. Additionally, the company is advancing other diagnostic substances and therapeutic programs, with a collaboration agreement in place with IMV Inc. to explore combined immunotherapeutic effects. Founded in 1983 and headquartered in Dublin, Ohio, Navidea Biopharmaceuticals previously operated under the name Neoprobe Corporation until 2012.